We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Perillyl alcohol for pediatric TP53- and RAS-mutated SHH-medulloblastoma: an in vitro and in vivo translational pre-clinical study.
- Authors
Silva, Marcela de Oliveira; de Sousa, Graziella Ribeiro; Simões, Sarah Capelupe; Nicolucci, Patrícia; Tamashiro, Edwin; Saggioro, Fabiano; de Oliveira, Ricardo Santos; Brassesco, María Sol
- Abstract
Purpose: Inhalation of perillyl alcohol (POH) recently emerged as an investigational promising antiglioma strategy. However, little attention has been paid to its therapeutic potential for other brain tumors, especially in the pediatric setting. Methods: The effects of POH were explored in medulloblastoma cell models belonging to the SHH variant with activation of RAS (ONS-76) or with TP53 mutations (DAOY and UW402), by means of proliferation and invasion assays. Interactions with methotrexate, thiotepa, or ionizing radiation were also assessed. Mice bearing subcutaneous tumors were treated with intraperitoneal injections. Alternatively, animals with intracranial tumors were exposed to intranasal POH alone or combined with radiation. Tumor growth was measured by bioluminescence. Analyses of cytotoxicity to the nasal cavity were also performed, and the presence of POH in the brain, lungs, and plasma was surveyed through chromatography/mass spectrometry. Results: POH decreased cell proliferation and colony formation, with conspicuous death, though the invasive capacity was only affected in the NRAS-mutated cell line. Median-drug effect analysis displayed synergistic combinations with methotrexate. Otherwise, POH showed to be a reasonable radiosensitizer. In vivo, intraperitoneal injection significantly decreased tumor volume. However, its inhalation did not affect orthotopic tumors, neither alone or followed by cranial irradiation. Nasal cavity epithelium showed unimportant alterations, though, no traces of POH or its metabolites were detected in tissue samples. Conclusion: POH presents robust in vitro antimedulloblastoma effects and sensitizes cell lines to other conventional therapeutics, reducing tumor volume when administered intraperitoneally. Nevertheless, further improvement of delivery devices and/or drug formulations are needed to better characterize its effectiveness through inhalation.
- Subjects
IONIZING radiation; NASAL mucosa; INTRAPERITONEAL injections; NASAL cavity; INTRACRANIAL tumors; TUMOR growth
- Publication
Child's Nervous System, 2021, Vol 37, Issue 7, p2163
- ISSN
0256-7040
- Publication type
Article
- DOI
10.1007/s00381-021-05115-w